Lidocaine Hydrochloride Injection Shortage: Current Availability and Manufacturer Updates

Source: FDA · United States

According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.

The FDA has reported a current shortage of Lidocaine Hydrochloride Injection, a medication used for anesthesia and pediatric care, with varying availability across multiple manufacturers.

What this FDA drug-shortage notice tells you, and what most readers miss

This notice was issued by FDA on February 11, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Lidocaine-Hydrochloride) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

What's in Shortage

Generic Name: Lidocaine Hydrochloride Injection
Brand Names: XYLOCAINE MPF, XYLOCAINE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE AND DEXTROSE
Dosage Form: Injection
Therapeutic Category: Anesthesia, Pediatric
Current Status: Current Shortage

This shortage was first posted on February 22, 2012, and was most recently updated on February 5, 2026.

Which Manufacturers Are Affected

Supply status varies significantly by manufacturer and specific product presentation:

  • Fresenius Kabi USA, LLC (888-386-1300): Mixed availability. While many presentations of Xylocaine and Lidocaine Hydrochloride are available, several specific doses (including 5 mg/1 mL, 15 mg/1 mL, 10 mg/1 mL, and 20 mg/1 mL) are currently unavailable. The manufacturer notes that next release dates are not available at this time.
  • Eugia US LLC (888-238-7880): Mixed availability. Several presentations are available, but multiple others are on backorder with recovery dates listed as To Be Determined (TBD).
  • B. Braun Medical Inc. (800-227-2862): Currently reporting products as Available.
  • Baxter Healthcare (888-229-0001): Currently reporting products as Available.
  • Spectra Medical Devices, LLC (978-657-0889 ext. 5231): Currently reporting products as Available.

Patients and providers are encouraged to check with wholesalers for current inventory levels.

Why There's a Shortage

No specific underlying reason for the shortage was provided in the current FDA report. Manufacturers have noted backorders and unavailable release dates for specific presentations.

What Patients Should Do

If you are scheduled for a procedure requiring Lidocaine Hydrochloride Injection, please consider the following steps:

  • Consult Your Healthcare Provider: Speak with your doctor or surgeon about the availability of the medication for your upcoming treatment.
  • Talk to Your Pharmacist: Pharmacists often have the most up-to-date information on local stock and can check with multiple wholesalers.
  • Contact Manufacturers: You may use the contact information provided above to inquire about specific product availability.

Disclaimer: This article is for informational purposes only. Patients should always consult with their healthcare provider or a qualified medical professional regarding their treatment and any potential medication alternatives.

Source

Information provided by the FDA Drug Shortage Database.

Original source: FDA Official Notice ↗

All Drug Shortages →

Frequently Asked Questions

Common questions about this FDA drug-shortage notice.

What is this FDA drug-shortage notice about?
The FDA has reported a current shortage of Lidocaine Hydrochloride Injection, a medication used for anesthesia and pediatric care, with varying availability across multiple manufacturers.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "medium" severity. Stay informed and follow agency guidance.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more Drug Shortages updates?
Browse the full Drug Shortages feed on Areazine at areazine.com/drug-shortages/ for the latest updates from FDA and other agencies.